Table 1. Summary of all currently published PSMA-based ADC clinical trials.

PSMA: Prostate-specific membrane antigen; ADC: Antibody drug conjugate.

PSMA-based antibody-drug conjugates
Antibody drug conjugate	Drug type	Antibody/target	Cancer	Developer	Study phase	NCT Number
MLN2704	Maytansinoid DM1	hJ591/PSMA	Prostate	Millennium Pharmaceuticals	Phase I and I/II	NCT00052000 and NCT00070837
PSMA-ADC	Monomethyl auristatin E (MMAE)	anti-PSMA fully human IgG1/PSMA	Prostate	Progenics/Seattle Genetics	Phase I and II	NCT01414283 and NCT01695044